Home » Stocks » CLRB

Cellectar BioSciences, Inc. (CLRB)

Stock Price: $1.12 USD 0.03 (2.75%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
After-hours: $1.11 -0.01 (-0.89%) Jul 23, 7:38 PM
Market Cap 59.05M
Revenue (ttm) n/a
Net Income (ttm) -17.49M
Shares Out 48.14M
EPS (ttm) -0.59
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $1.12
Previous Close $1.09
Change ($) 0.03
Change (%) 2.75%
Day's Open 1.10
Day's Range 1.08 - 1.15
Day's Volume 693,006
52-Week Range 1.01 - 2.98

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Preclinical Data Supports Further Development of Multiple Novel Phospholipid Drug Conjugates (PDCs) Preclinical Data Supports Further Development of Multiple Novel Phospholipid Drug Conjugates (PDCs)

1 week ago - GlobeNewsWire

Cellectar Biosciences Inc (NASDAQ: CLRB) has collaborated with LegoChemBio to develop and commercialize phospholipid drug conjugates (PDCs). Under the agreement, the two companies have the option to joi...

1 week ago - Benzinga

Development of Multiple Novel PDCs Development of Multiple Novel PDCs

1 week ago - GlobeNewsWire

FLORHAM PARK, N.J., July 08, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for th...

2 weeks ago - GlobeNewsWire

FLORHAM PARK, N.J., June 24, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for th...

1 month ago - GlobeNewsWire

Cellectar Biosciences Inc (NASDAQ: CLRB) announced updated data at the American Society of Clinical Oncology (ASCO) Annual Meeting from Phase 2 CLOVER-1 study of CLR 131 in relapsed/refractory B-cell he...

1 month ago - Benzinga

Mean treatment free remission 1.1 years and remains ongoing

1 month ago - GlobeNewsWire

Management to host a KOL call with Dr. Sikandar Ailawadhi, M.D., lead investigator on June 4 at 10:00 am Management to host a KOL call with Dr. Sikandar Ailawadhi, M.D., lead investigator on June 4 at 1...

2 months ago - GlobeNewsWire

FLORHAM PARK, N.J., May 14, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the...

2 months ago - GlobeNewsWire

Initiated pivotal study of CLR 131 in Waldenstrom's macroglobulinemia (WM) Received European Orphan Drug Designation for CLR 131 in WM

2 months ago - GlobeNewsWire

New patent covers phospholipid-ether analogs combined with various small molecule chemotherapeutics and methods of use for PDCs™ New patent covers phospholipid-ether analogs combined with various small ...

2 months ago - GlobeNewsWire

FLORHAM PARK, N.J., March 11, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercializ...

4 months ago - GlobeNewsWire

FLORHAM PARK, N.J., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercializa...

5 months ago - GlobeNewsWire

Benefits include 10 years of market exclusivity in the European Union Benefits include 10 years of market exclusivity in the European Union

5 months ago - GlobeNewsWire

FLORHAM PARK, N.J., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercializat...

6 months ago - GlobeNewsWire

FLORHAM PARK, N.J., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercializat...

7 months ago - GlobeNewsWire

FLORHAM PARK, N.J., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercializat...

7 months ago - GlobeNewsWire

Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of September. At Insider ...

7 months ago - Insider Monkey

FLORHAM PARK, N.J., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercializat...

8 months ago - GlobeNewsWire

The dollar has not only strengthened in recent times but it seems there is even more room for growth. So, let's find out which stocks stand to benefit from dollar's comeback.

Other stocks mentioned: APEI, AQMS, BZH
9 months ago - Zacks Investment Research

Cellectar Biosciences Phase 2 Data In Multiple Myeloma Is Worth A Look

10 months ago - Seeking Alpha

40% overall response rate (ORR) with a total administered dose of 60 mCi or greater 40% overall response rate (ORR) with a total administered dose of 60 mCi or greater

10 months ago - GlobeNewsWire

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.

Other stocks mentioned: AWR, CVEO, KIN, POR
10 months ago - Zacks Investment Research

Poster highlights the Phase 2a study data in relapsed or refractory lymphoplasmacytic lymphoma (LPL)/Waldenstrom’s macroglobulinemia (WM)

11 months ago - GlobeNewsWire

FLORHAM PARK, N.J., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...

11 months ago - GlobeNewsWire

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.

Other stocks mentioned: ACRX, BDSI, BNFT, LNT
11 months ago - Zacks Investment Research

Data highlight initial results of 100% overall response rate from ongoing Phase 2 trial in Relapsed or Refractory lymphoplasmacytic lymphoma (LPL)/Waldenstrom’s Macroglobulinemia (WM) Data highlight ini...

1 year ago - GlobeNewsWire

Cellectar Biosciences (NASDAQ: CLRB) shares are trading higher on Wednesday after Oppenheimer initiated coverage on the stock with an Outperform rating and $5 price target.

1 year ago - Benzinga

FLORHAM PARK, N.J., July 01, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...

1 year ago - GlobeNewsWire

Covers composition of matter and method of use into 2036 for proprietary PLE analogs in combination with various small molecule chemotherapeutics Covers composition of matter and method of use into 2036...

1 year ago - GlobeNewsWire

FLORHAM PARK, N.J., June 05, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq: CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of dr...

1 year ago - GlobeNewsWire

FLORHAM PARK, N.J., June 03, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...

1 year ago - GlobeNewsWire

Designation Comes with Financial and Scientific Incentives Designation Comes with Financial and Scientific Incentives

1 year ago - GlobeNewsWire

FLORHAM PARK, N.J., May 26, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization ...

1 year ago - GlobeNewsWire

Patent covers the phospholipid ether (PLE) delivery vehicle combined with I-131 and I-125 Patent covers the phospholipid ether (PLE) delivery vehicle combined with I-131 and I-125

1 year ago - GlobeNewsWire

FLORHAM PARK, N.J., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...

1 year ago - GlobeNewsWire

FLORHAM PARK, N.J., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...

1 year ago - GlobeNewsWire

30% overall response rate seen with an average progression free survival of 4.5 months and an acceptable and expected safety profile

1 year ago - GlobeNewsWire

FLORHAM PARK, N.J., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...

1 year ago - GlobeNewsWire

FLORHAM PARK, N.J., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...

1 year ago - GlobeNewsWire

Data showed durable clinical responses, including a 33% overall response rate (ORR) and 16.6% complete response (CR) Data showed durable clinical responses, including a 33% overall response rate (ORR) a...

1 year ago - GlobeNewsWire

FLORHAM PARK, N.J., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercializatio...

1 year ago - GlobeNewsWire

Data presented at the 17th International Myeloma Workshop

1 year ago - GlobeNewsWire

FLORHAM PARK, N.J., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercializatio...

1 year ago - GlobeNewsWire

The biotechnology space is an exciting one with incredible potential for investors.

Other stocks mentioned: AMRN, BMRN, GWPH, SNY
2 years ago - Benzinga

About CLRB

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131, which is in Phase II clinical study in patients with relapsed or refractory (R/R) Waldenstrom's macroglobulinemia (WM) and B-cell malignancies; and Phase IIB clinical study in r/r multiple myeloma (MM) patients, as well as Phase I study for various pediatric cancers, R/R head and neck cancers, and R/R MM. The company ... [Read more...]

Industry
Biotechnology
Founded
2002
CEO
James Caruso
Employees
11
Stock Exchange
NASDAQ
Ticker Symbol
CLRB
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for CLRB stock is "Buy." The 12-month stock price forecast is 5.98, which is an increase of 433.93% from the latest price.

Price Target
$5.98
(433.93% upside)
Analyst Consensus: Buy